Tumour microenvironment: Modulating effects, challenges, and future perspectives of oncolytic virotherapy in Astrocytoma treatment

[1]  Li Yang,et al.  Engineering strategies to enhance oncolytic viruses in cancer immunotherapy , 2022, Signal Transduction and Targeted Therapy.

[2]  V. Chekhonin,et al.  Infection of non-cancer cells: A barrier or support for oncolytic virotherapy? , 2022, Molecular therapy oncolytics.

[3]  M. Hitt,et al.  Genetic Modifications That Expand Oncolytic Virus Potency , 2022, Frontiers in Molecular Biosciences.

[4]  Jiayi Zeng,et al.  Oncolytic Viro-Immunotherapy: An Emerging Option in the Treatment of Gliomas , 2021, Frontiers in Immunology.

[5]  J. Markert,et al.  Immunovirotherapy for the Treatment of Glioblastoma and Other Malignant Gliomas. , 2021, Neurosurgery clinics of North America.

[6]  M. Lamfers,et al.  Personalizing Oncolytic Virotherapy for Glioblastoma: In Search of Biomarkers for Response , 2021, Cancers.

[7]  Jia Wei,et al.  Combining Oncolytic Viruses With Cancer Immunotherapy: Establishing a New Generation of Cancer Treatment , 2020, Frontiers in Immunology.

[8]  T. Das.  Astrocytoma , 2020, Definitions.

[9]  G. Freeman,et al.  Correction: Arming an Oncolytic Herpes Simplex Virus Type 1 with a Single-chain Fragment Variable Antibody against PD-1 for Experimental Glioblastoma Therapy , 2020, Clinical Cancer Research.

[10]  G. Kroemer,et al.  Heating it up: Oncolytic viruses make tumors ‘hot’ and suitable for checkpoint blockade immunotherapies , 2018, Oncoimmunology.

[11]  C. Lau,et al.  Intravenous injection of oncolytic picornavirus SVV-001 prolongs animal survival in a panel of primary tumor-based orthotopic xenograft mouse models of pediatric glioma. , 2013, Neuro-oncology.

[12]  G. Nuovo,et al.  Cell Carriage, Delivery, and Selective Replication of an Oncolytic Virus in Tumor in Patients , 2012, Science Translational Medicine.

[13]  M. Caligiuri,et al.  Extracellular matrix protein CCN1 limits oncolytic efficacy in glioma. , 2012, Cancer research.

[14]  B. Kaur,et al.  Impact of tumor microenvironment on oncolytic viral therapy. , 2010, Cytokine & growth factor reviews.

[15]  C. Naus,et al.  Dose‐dependent differential upregulation of CCN1/Cyr61 and CCN3/NOV by the gap junction protein Connexin43 in glioma cells , 2008, Journal of cellular biochemistry.

[16]  Yuri Kotliarov,et al.  Genomic Changes and Gene Expression Profiles Reveal That Established Glioma Cell Lines Are Poorly Representative of Primary Human Gliomas , 2008, Molecular Cancer Research.

[17]  C. Hartmann,et al.  Combined treatment of pediatric high‐grade glioma with the oncolytic viral strain MTH‐68/H and oral valproic acid , 2006, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[18]  B. Bodey,et al.  MTH-68/H Oncolytic Viral Treatment in Human High-Grade Gliomas , 2004, Journal of Neuro-Oncology.

[19]  J. Markert,et al.  Design of a Phase I Clinical Trial to Evaluate M032, a Genetically Engineered HSV-1 Expressing IL-12, in Patients with Recurrent/Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma, or Gliosarcoma. , 2016, Human gene therapy. Clinical development.

[20]  J. Markert,et al.  Design of a Phase I Clinical Trial to Evaluate M032, a Genetically Engineered HSV-1 Expressing IL-12, in Patients with Recurrent/Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma, or Gliosarcoma. , 2016, Human gene therapy. Clinical development.